EUVIMEDEUVIMED entdecken
Open Access

The Effects of Prescribed Medications on Depressive Symptoms and Neurocognitive Performance in People With HIV

Asante R Kamkwalala iD, Avery Matthews, Ankita Garg iD, Upal Roy, Qing Ma iD, Maile Karris, Erin Sundermann iD, Ronald J Ellis iD, Patricia K Riggs, Mattia Trunfio iD, Jennifer Blanchard, David J Moore iD und 2 weitere

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciae518 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Asante R Kamkwalala und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: HIV Infections, Depression, Anti-HIV Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIDA NIH HHS, NIMH NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alterations in brain function and structure, such as depression and neurocognitive impairment, continue to occur in people with human immunodeficiency virus (HIV, PWH) taking suppressive antiretroviral therapy (ART). The lifespan of PWH has improved but the healthspan remains worse than people without HIV, in part because of aging-related diseases. As a result, polypharmacy is common and increases the risk of drug-drug interactions and adverse reactions.

Methods

This cross-sectional project investigated the relationship between 7 medication-related metrics (including anticholinergic burden), depressive symptoms, and neurocognitive performance in 491 PWH at a single center in the United States. All participants were taking ART and had plasma HIV RNA ≤ 200 copies/mL.

Results

Participants had taken ART for a mean of 6.5 years, and most (57.6%) had CD4+ T-cells >500/µL. All 7 medication-related metrics were associated with worse global neurocognitive performance (P value <.0001 to .0087). Multivariable models confirmed that higher anticholinergic burden (P = .040) and use of benzodiazepines (P = .033), antidepressants (P = .0011), and more total medications (P = .059) were associated with more depressive symptoms (model P < .0001). Use of benzodiazepines (P = .0024) and opiates (P = .043) along with higher anticholinergic burden (P = .066) were also associated with worse neurocognitive performance. Benzodiazepine use was associated with worse performance in all domains and opiate use was associated with worse performance in processing speed, motor function, executive function, and working memory.

Conclusions

Use of benzodiazepines, opiates, and anticholinergic drugs contribute to cognitive and mood disorders in PWH. When possible, modifying or deprescribing medications may be beneficial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsDepressionAnti-HIV AgentsHumansMaleFemaleCross-Sectional StudiesMiddle AgedAdultPolypharmacyCholinergic AntagonistsAntidepressive AgentsCognition

Stichwörter der Autor:innen

HIVanticholinergiccognitiondepressionpolypharmacy

Substanzen

Cholinergic AntagonistsAnti-HIV AgentsAntidepressive Agents

Autor:innen und Institutionen

  • Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA.
  • Department of Psychiatry, University of Texas Health Science Center, San Antonio, Texas, USA.
  • Department of Infectious Diseases, University of Georgia, Athens, Georgia, USA.
  • Department of Health and Biomedical Sciences, University of Texas Rio Grande Valley, Brownsville, Texas, USA.
  • Department of Pharmacy Practice, University at Buffalo, Buffalo, New York, USA.
  • Department of Medicine, University of California, San Diego, California, USA.

ORCID-Profile: Asante R Kamkwalala, Ankita Garg, Qing Ma, Erin Sundermann, Ronald J Ellis, Mattia Trunfio, David J Moore, Scott L Letendre

Förderung

  • NIAID NIH HHS
  • NIDA NIH HHS
  • NIMH NIH HHS
  • NIA NIH HHS
  • NINDS NIH HHS
  • National Institute on Aging
  • National Institute of Mental Health
  • National Institute on Drug Abuse

Zitieren

APA

Kamkwalala, A. R., Matthews, A., Garg, A., Roy, U., Ma, Q., Karris, M., Sundermann, E., Ellis, R. J., Riggs, P. K., Trunfio, M., Blanchard, J., Moore, D. J., Rubin, L. H., & Letendre, S. L. (2025). The Effects of Prescribed Medications on Depressive Symptoms and Neurocognitive Performance in People With HIV. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae518

Vancouver

Kamkwalala AR, Matthews A, Garg A, Roy U, Ma Q, Karris M, et al. The Effects of Prescribed Medications on Depressive Symptoms and Neurocognitive Performance in People With HIV. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciae518

BibTeX
@article{Kamkwalala2025,
  author = {Kamkwalala, Asante R and Matthews, Avery and Garg, Ankita and Roy, Upal and Ma, Qing and Karris, Maile and Sundermann, Erin and Ellis, Ronald J and Riggs, Patricia K and Trunfio, Mattia and Blanchard, Jennifer and Moore, David J and Rubin, Leah H and Letendre, Scott L},
  title = {The Effects of Prescribed Medications on Depressive Symptoms and Neurocognitive Performance in People With HIV},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciae518}
}
Kostenlos starten →